Anti-IL-36R antibodies, potentially useful for the treatment of psoriasis: a patent evaluation of WO2013074569
Authors:
- Laura Korb FerrisLFLaura Korb Ferris
- 23 January 2014
- journal article
- Published by Informa Healthcare in Expert Opinion on Therapeutic Patents
- Vol. 24 (4) , 477-479
Abstract
The IL-36 family of cytokines and receptors seems to play a role in the pathogenesis of both pustular psoriasis, and the much more common variant, plaque-type psoriasis. Human skin biopsies from patients with psoriasis show overexpression of IL-36 and mice that lack the inhibitory IL-36 receptor (IL-36Ra) antagonist develop psoriasis, suggesting that signaling through the IL-36R may drive the skin lesions of psoriasis. Currently, no drugs targeting IL-36 are used in the treatment of psoriasis. The patent WO2013074569 describes an antibody to the IL-36R that is proposed as a potential therapy for psoriasis.Keywords
This publication has 11 references indexed in Scilit:
- The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synoviumAnnals of the Rheumatic Diseases, 2013
- Novel IL36RN mutation in a Japanese case of early onset generalized pustular psoriasisThe Journal of Dermatology, 2013
- New Insights in the Immunobiology of IL-1 Family MembersFrontiers in Immunology, 2013
- Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalkJournal of Clinical Investigation, 2012
- Inter-Regulation of Th17 Cytokines and the IL-36 Cytokines In Vitro and In Vivo: Implications in Psoriasis PathogenesisJournal of Investigative Dermatology, 2011
- Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular PsoriasisNew England Journal of Medicine, 2011
- IL-1F5, -F6, -F8, and -F9: A Novel IL-1 Family Signaling System That Is Active in Psoriasis and Promotes Keratinocyte Antimicrobial Peptide ExpressionThe Journal of Immunology, 2011
- IL-1RL2 and Its Ligands Contribute to the Cytokine Network in PsoriasisThe Journal of Immunology, 2010
- Opposing activities of two novel members of the IL-1 ligand family regulate skin inflammationJournal of Experimental Medicine, 2007
- Interleukin (IL)-1F6, IL-1F8, and IL-1F9 Signal through IL-1Rrp2 and IL-1RAcP to Activate the Pathway Leading to NF-κB and MAPKsJournal of Biological Chemistry, 2004